{"gene":"RAPGEF4","run_date":"2026-06-10T06:43:36","timeline":{"discoveries":[{"year":2000,"finding":"cAMP-GEFII (RAPGEF4) directly binds to Rim (Rab3-interacting molecule) and a new isoform Rim2, and mediates cAMP-induced, Ca2+-dependent exocytosis that is not blocked by PKA inhibitors, establishing it as a direct cAMP target in regulated exocytosis via a PKA-independent mechanism.","method":"Co-immunoprecipitation/binding assays, reconstituted exocytosis system, PKA inhibitor pharmacology","journal":"Nature cell biology","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — binding interaction demonstrated with functional reconstitution, PKA-independent mechanism established with inhibitor controls, foundational study replicated by multiple subsequent labs","pmids":["11056535"],"is_preprint":false},{"year":2001,"finding":"The cAMP-GEFII–Rim2 pathway mediates PKA-independent incretin-potentiated insulin secretion in native pancreatic beta-cells; antisense knockdown of cAMP-GEFII alone inhibited incretin-potentiated secretion ~50%, and combined with PKA inhibitor H-89 inhibited ~80–90%, demonstrating both pathways act in parallel.","method":"Antisense oligodeoxynucleotide knockdown in pancreatic islets, insulin secretion assays, PKA inhibitor (H-89) pharmacology","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — loss-of-function in native tissue with defined secretory phenotype, replicated in subsequent studies, two orthogonal inhibition strategies used","pmids":["11598134"],"is_preprint":false},{"year":2001,"finding":"The EPAC2/cAMP-GEFII gene encodes a liver-specific isoform (79 kDa) initiated from exon 10, lacking the first cAMP-binding domain and DEP domain, that retains GEF activity toward Rap1, demonstrating alternative promoter usage creates functionally distinct isoforms.","method":"cDNA cloning, primer extension, RT-PCR, in situ hybridization, immunoblot, GEF activity assay","journal":"Genomics","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — multiple orthogonal molecular methods (cloning, expression mapping, enzymatic assay) in a single study","pmids":["11707077"],"is_preprint":false},{"year":2002,"finding":"cAMP-GEFII forms a complex with Rim2 and Piccolo; Piccolo acts as a Ca2+-sensor by forming Ca2+-dependent homodimers and heterodimers with Rim2, and antisense knockdown of Piccolo inhibits cAMP analog-induced insulin secretion, implicating the cAMP-GEFII·Rim2·Piccolo complex in cAMP-induced exocytosis.","method":"Co-immunoprecipitation, dimerization assays (Ca2+-dependent), antisense oligodeoxynucleotide knockdown in pancreatic islets, insulin secretion assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal binding assays with functional knockdown validation, replicated across multiple subsequent studies","pmids":["12401793"],"is_preprint":false},{"year":2003,"finding":"SUR1 (sulfonylurea receptor 1, a subunit of the KATP channel) physically interacts with cAMP-GEFII through its nucleotide-binding fold 1 (NBF1); this interaction is decreased by high concentrations of cAMP. SUR1-deficient beta-cells completely lack the PKA-independent component of cAMP-stimulated exocytosis, and this defect is associated with impaired cAMP-dependent Cl- influx into granules required for granule priming.","method":"Co-immunoprecipitation, antisense knockdown, capacitance measurements in SUR1-knockout mouse beta-cells, insulin release assays","journal":"The Journal of general physiology","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — genetic knockout combined with electrophysiology and interaction assays, multiple orthogonal methods","pmids":["12601083"],"is_preprint":false},{"year":2003,"finding":"cAMP-GEFII mediates GLP-1-stimulated ryanodine receptor-dependent Ca2+ release from intracellular stores and subsequent mitochondrial ATP synthesis in MIN6 beta-cells; a dominant-negative form of cAMP-GEFII (G114E,G422D) blocked this xestospongin C-insensitive (RyR-mediated) component of [ATP]m increase.","method":"Dominant-negative mutant expression, pharmacological inhibitors (xestospongin C, ryanodine, H-89), mitochondrial ATP/Ca2+ imaging in MIN6 cells","journal":"The Biochemical journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — dominant-negative mutagenesis with functional readout in a single lab, two orthogonal inhibitor strategies","pmids":["12410638"],"is_preprint":false},{"year":2003,"finding":"cAMP-GEFII, Rim2, Piccolo, SUR1, and L-type VDCC (alpha1 1.2 subunit) form an integrated signaling complex in pancreatic beta-cells: SUR1 interacts with cAMP-GEFII via NBF1; Rim2 interacts with cAMP-GEFII and requires its Rab3-binding region for plasma membrane localization; Piccolo and Rim2 both bind directly to the VDCC alpha1 1.2 subunit. This complex integrates ATP, cAMP, and Ca2+ signals for insulin granule exocytosis.","method":"Co-immunoprecipitation, immunolocalization in MIN6 cells, dominant-negative Rim2 overexpression with exocytosis measurements","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple binary and multiprotein interactions demonstrated, dominant-negative functional validation, consistent with prior and subsequent studies","pmids":["14660679"],"is_preprint":false},{"year":2004,"finding":"SUR1, cAMP-GEFII, and Piccolo can form a trimeric complex; interaction of cAMP-GEFII with SUR1 is inhibited by 8-bromo-cAMP (but not by ATP), and this inhibition persists in the presence of ATP, indicating cAMP regulates the assembly state of the KATP/cAMP-GEFII/Piccolo/VDCC complex.","method":"Co-immunoprecipitation with cAMP analog treatments, pull-down assays","journal":"Diabetes","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — biochemical interaction assays with pharmacological perturbation, single lab but consistent with prior structural complex studies","pmids":["15561922"],"is_preprint":false},{"year":2005,"finding":"In mouse melanotrophs, cAMP stimulates exocytosis through both PKA-dependent and Epac2/cAMP-GEFII-dependent pathways; the 8-pCPT-2Me-cAMP (Epac-selective agonist) specifically potentiated the linear (rapidly releasable) component of exocytosis, while PKA inhibition abolished the threshold component, demonstrating separable roles.","method":"Whole-cell patch-clamp capacitance measurements in pituitary tissue slices, pharmacological dissection with Epac-selective agonist, PKA inhibitors (H-89, Rp-cAMPS), and PKA-selective agonist (6-Phe-cAMP)","journal":"The Journal of physiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — electrophysiological measurements with selective pharmacological tools in native tissue, single lab","pmids":["15994184"],"is_preprint":false},{"year":2007,"finding":"Anthrax edema toxin-generated cAMP inhibits endothelial cell chemotaxis via Epac2 (RAPGEF4) and its substrate Rap1; activated Epac or Rap1 induces cytoskeletal changes and blocks chemotaxis in human microvascular endothelial cells, and ET induces transcription of Epac2/RAPGEF4.","method":"Activated Epac/Rap1 overexpression, endothelial cell chemotaxis assays, cytoskeletal imaging","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gain-of-function with defined morphological and chemotaxis phenotype, single lab, two orthogonal interventions (Epac and Rap1 activation)","pmids":["17491018"],"is_preprint":false},{"year":2009,"finding":"The N-terminal cAMP-binding domain A of Epac2A is critical for its plasma membrane localization in MIN6 cells; Epac2B (a splice variant lacking this domain) localizes to the cytoplasm and fails to potentiate hormone secretion, whereas adding a membrane-targeting signal to Epac2B restores its secretory function.","method":"Immunocytochemistry, domain deletion/splice variant analysis, membrane-targeting signal fusion, insulin secretion assay in MIN6 cells, characterization of Epac2-knockout mice","journal":"Journal of cellular physiology","confidence":"High","confidence_rationale":"Tier 2 / Strong — domain mapping with functional rescue experiment, multiple orthogonal approaches (localization + secretion + membrane targeting), supported by KO mouse model","pmids":["19170062"],"is_preprint":false},{"year":2009,"finding":"Epac2 (RAPGEF4) activation in cortical neurons induces spine shrinkage, increases spine motility, removes GluR2/3-containing AMPA receptors from synapses, and depresses excitatory transmission; inhibition of Epac2 promotes spine enlargement and stabilization. Epac2 interaction with neuroligin promotes membrane recruitment and enhances its GEF activity. Autism-associated rare missense mutations in EPAC2 alter basal and neuroligin-stimulated GEF activity, dendritic Rap signaling, synaptic protein distribution, and spine morphology.","method":"Epac2 activation/inhibition in cultured rat cortical neurons, live imaging of spine dynamics, electrophysiology, GluR2 immunostaining, neuroligin co-immunoprecipitation, GEF activity assays for autism-associated mutants","journal":"Nature neuroscience","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — multiple orthogonal methods (imaging, electrophysiology, biochemistry, mutagenesis), neuroligin interaction validated by Co-IP, GEF activity directly measured for mutants","pmids":["19734897"],"is_preprint":false},{"year":2009,"finding":"SNAP-25 physically interacts with both cAMP-GEFII and RIM2; truncation of SNAP-25 C-terminus abolishes cAMP potentiation of rapid exocytosis from the immediately releasable pool (the cAMP-GEFII/PKA-independent pathway) in insulin-secreting cells, while reserve pool mobilization by cAMP is preserved.","method":"Capacitance measurements, protein-binding assays, Western blot, INS-1 cells overexpressing truncated SNAP-25 or BoNT/A","journal":"American journal of physiology. Endocrinology and metabolism","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — interaction assay combined with functional exocytosis measurements, single lab with two orthogonal tools (truncation and toxin)","pmids":["19509185"],"is_preprint":false},{"year":2012,"finding":"Sulfonylureas (except gliclazide) activate Epac2/Rap1 signaling to promote insulin granule exocytosis; Epac2 is required for the full insulinotropic effect of sulfonylureas as well as for incretin-potentiated insulin secretion; gliclazide uniquely does not activate Epac2 and is specific to KATP channel inhibition.","method":"Pharmacological comparison of sulfonylureas, Epac2-dependent signaling assays, Rap1 activation assays","journal":"Diabetes, obesity & metabolism","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — review synthesizing experimental findings from prior studies with mechanistic specificity on drug-target selectivity; single group, multiple experimental approaches referenced","pmids":["22118705"],"is_preprint":false},{"year":2013,"finding":"GLP-1 receptor activation promotes translocation of Epac2 (RAPGEF4) to the cardiomyocyte membrane; Epac2 deficiency eliminates GLP-1R-dependent stimulation of atrial natriuretic peptide (ANP) secretion from cardiac atria, establishing a GLP-1R→Epac2→ANP axis that reduces blood pressure.","method":"Epac2 membrane translocation imaging, Epac2-knockout mice (ANP secretion assays), conditioned medium aortic ring relaxation assay, GLP-1R-knockout and Nppa-knockout mice","journal":"Nature medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic knockout with defined physiological phenotype, membrane translocation imaging, multiple KO lines used to dissect pathway","pmids":["23542788"],"is_preprint":false},{"year":2013,"finding":"In Xenopus pronephros, Rapgef4-dependent signaling downstream of Gnas/cAMP controls exo- and endocytosis and regulates proximal tubular growth; a Rapgef4-specific agonist in a human proximal tubular cell line increased albumin uptake and decreased secretion, phenocopying cholera toxin effects.","method":"Antisense morpholino knockdown in Xenopus embryos, pharmacological agonist/antagonist treatments, FITC-albumin uptake/secretion assays in human proximal tubular cells","journal":"Developmental biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — morpholino loss-of-function with defined tubular phenotype and pharmacological validation in human cell line, single lab","pmids":["23352791"],"is_preprint":false},{"year":2014,"finding":"EPAC2 (RAPGEF4) in endometrial glandular epithelial cells regulates calreticulin (CALR) protein and mRNA expression; EPAC2 or CALR knockdown suppresses PKA-agonist-induced LIF and COX2 (PTGS2) expression and PGE2 secretion, and increases cellular senescence markers, establishing an EPAC2→CALR→LIF/PTGS2 axis in endometrial gland function.","method":"siRNA knockdown of EPAC2 and CALR in EM1 cells, EPAC-selective and PKA-selective cAMP analogs, gene/protein expression analysis, senescence-associated beta-galactosidase assay","journal":"Journal of molecular endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA knockdown with pathway dissection using selective cAMP analogs, single lab, two orthogonal knockdowns","pmids":["25378661"],"is_preprint":false},{"year":2015,"finding":"Crystallographic analysis of Epac2 revealed that cAMP-induced activation is accompanied by dynamic structural changes, and the protein functions as a direct cAMP sensor with GEF activity toward Rap.","method":"Crystallographic analysis (structural review synthesizing prior crystal structures)","journal":"Gene","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — review citing crystallographic data, structural basis for cAMP-induced conformational activation established; treated as Tier 1 for structural finding but Moderate given review format","pmids":["26390815"],"is_preprint":false},{"year":2015,"finding":"PACAP-38 activation of Epac2/Rapgef4 downstream signaling (p38 phosphorylation) requires AC6 but not AC7; this selectivity depends on the vicinal constraint of PAC1 receptor and AC6, while coupling of Epac2 to p38 determines how cAMP is parcellated to physiological responses in neuroendocrine PC12 cells.","method":"lentiviral shRNA knockdown of AC6 and AC7, PACAP-38 stimulation, phospho-p38 and phospho-CREB immunoblotting, methyl-beta-cyclodextrin cholesterol depletion","journal":"Molecular pharmacology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — selective knockdown with defined signaling readout, two orthogonal approaches (genetic and pharmacological disruption of membrane microdomains), single lab","pmids":["25769305"],"is_preprint":false},{"year":2016,"finding":"Epac2-knockout mice exhibit anxiety, depression, learning and memory deficits, and impaired hippocampal cell proliferation; Prozac (fluoxetine, SSRI) treatment ameliorates these phenotypes in Epac2-/- mice, establishing Epac2 as a required component of cAMP/serotonin-dependent mood regulation and hippocampal neurogenesis.","method":"Epac2-knockout mouse behavioral tests (open field, fear conditioning), hippocampal cell proliferation assay, SSRI treatment","journal":"Translational psychiatry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic knockout with multiple behavioral phenotypes and neurogenesis readout, single lab","pmids":["27598965"],"is_preprint":false},{"year":2019,"finding":"Epac2 (Rap-GEF4) controls fusion pore expansion during insulin exocytosis by acutely recruiting two pore-restricting proteins, amisyn and dynamin-1, to the exocytosis site; cAMP elevation via GLP-1 receptor agonists or sulfonylureas restricts and slows fusion pore expansion and peptide release via this Epac2-dependent mechanism; this effect is absent in Epac2-/- (Rapgef4-/-) mice or upon Epac2 pharmacological inactivation.","method":"Total internal reflection fluorescence (TIRF) imaging of fusion pore dynamics, Epac2-/- (Rapgef4-/-) knockout mice, pharmacological Epac2 inactivation, Epac2 overexpression, amisyn/dynamin-1 recruitment imaging","journal":"eLife","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — genetic KO with pharmacological validation, live imaging of pore dynamics, identification of recruited effectors (amisyn, dynamin-1), multiple orthogonal approaches","pmids":["31099751"],"is_preprint":false},{"year":2021,"finding":"RAPGEF4/EPAC2 is essential for exendin-4-induced autophagic flux in pancreatic beta-cells via a RAPGEF4/EPAC2→Ca2+→PPP3/calcineurin→TFEB axis; knockdown of RAPGEF4 prevents exendin-4-mediated cell survival and autophagic flux, while TFEB overexpression mimics the cytoprotective effect.","method":"siRNA knockdown of RAPGEF4 in INS-1E cells and human islets, chemical inhibitors, TFEB overexpression, db/db mouse in vivo treatment with exendin-4, lysosomal marker analysis","journal":"Autophagy","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA knockdown and overexpression with defined autophagic and survival phenotypes, in vivo validation, single lab","pmids":["34338148"],"is_preprint":false},{"year":2021,"finding":"EPAC2 overexpression in human microvascular endothelial cells suppresses Matrigel-driven tubulogenesis, inhibits cell migration, and changes cell morphology to a round shape; EPAC2 knockdown enhances tube formation, migration, and produces elongated cells with filopodia-like protrusions, identifying EPAC2 as a negative regulator of endothelial tube formation.","method":"RAPGEF4 overexpression and siRNA knockdown in HMVECs, Matrigel tube formation assay, migration assay, morphological imaging","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal gain- and loss-of-function with defined morphological and functional phenotypes, single lab","pmids":["34593918"],"is_preprint":false},{"year":2025,"finding":"RAPGEF4 is required for proper electrophysiological maturation (resting membrane potential and inward sodium current) of neurons in the primate prefrontal cortex; CHD8 knockdown in human and macaque organotypic slices impairs neuronal maturation by downregulating RAPGEF4, and restoring RAPGEF4 expression rescues electrophysiological maturation in CHD8-deficient neurons.","method":"Patch-seq, single-nucleus multiomic analyses, shRNA knockdown of CHD8, RAPGEF4 restoration experiments in organotypic slices from macaque and human","journal":"Neuron","confidence":"High","confidence_rationale":"Tier 2 / Strong — loss-of-function and rescue experiment in primate tissue with direct electrophysiological readout, multimodal analyses, two species validated","pmids":["40398411","37398253"],"is_preprint":false},{"year":2025,"finding":"Hepatic EPAC2 (RAPGEF4) knockdown does not affect hepatic amino acid catabolism gene suppression, hyperaminoacidemia, or alpha-cell hyperplasia caused by glucagon receptor (GCGR) blockade, indicating EPAC2 (unlike PKA) is not required for the liver-alpha-cell loop; the GCGR→GNAS→PKA pathway (not EPAC2) mediates hepatic amino acid catabolism.","method":"siRNA/ASO-mediated knockdown of GCGR, GNAS, PKA, and EPAC2 in mouse liver; measurement of plasma amino acids, hepatic amino acid catabolism genes, and alpha-cell mass","journal":"Diabetes","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — negative result for EPAC2 established by direct knockdown in vivo with defined metabolic phenotype, single lab; negative finding reported explicitly","pmids":["40095004"],"is_preprint":false},{"year":2026,"finding":"Rapgef4/Epac2 is upregulated in cortical excitatory and inhibitory neurons of Fmr1-knockout (fragile X syndrome model) mice; treatment with a specific EPAC2 antagonist restored cortical circuit function and ameliorated multiple behavioral phenotypes in Fmr1 KO mice, identifying EPAC2 as a potential therapeutic target for fragile X syndrome.","method":"Cell-type-specific translatomic sequencing (Patch-seq), EPAC2 antagonist treatment in Fmr1-KO mice, cortical circuit electrophysiology, behavioral assays","journal":"Neuron","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — translatomic identification plus pharmacological rescue with circuit and behavioral readouts, single lab","pmids":["42155452"],"is_preprint":false}],"current_model":"RAPGEF4 (Epac2/cAMP-GEFII) is a direct cAMP sensor and guanine nucleotide exchange factor for Rap1 that operates in a PKA-independent branch of cAMP signaling: upon cAMP binding—a conformational change structurally documented by crystallography—it forms a multiprotein complex with Rim2, Piccolo (Ca2+ sensor), SUR1, and L-type VDCC to integrate ATP, cAMP, and Ca2+ signals driving regulated exocytosis (most extensively characterized in pancreatic beta-cell insulin secretion); it also controls fusion pore expansion by recruiting amisyn and dynamin-1; in neurons it is activated by neuroligin, promotes Rap-dependent spine remodeling and synaptic depression, and is required for prefrontal cortex neuronal electrophysiological maturation; in cardiomyocytes it mediates GLP-1R-dependent ANP secretion; and in pancreatic beta-cells it drives GLP-1 agonist/sulfonylurea-stimulated secretion as well as GLP-1R agonist-induced autophagy via a Ca2+–calcineurin–TFEB axis."},"narrative":{"mechanistic_narrative":"RAPGEF4 (Epac2/cAMP-GEFII) is a direct cAMP sensor and guanine nucleotide exchange factor for Rap1 that drives a PKA-independent branch of cAMP signaling controlling regulated exocytosis and cellular morphology [PMID:11056535, PMID:26390815]. In pancreatic beta-cells it nucleates a multiprotein exocytotic complex with Rim2, the Ca2+ sensor Piccolo, the KATP-channel subunit SUR1, and the L-type voltage-dependent Ca2+ channel (alpha1 1.2 subunit), integrating ATP, cAMP, and Ca2+ signals to potentiate incretin- and sulfonylurea-stimulated insulin secretion through a PKA-independent mechanism [PMID:11056535, PMID:11598134, PMID:12401793, PMID:14660679, PMID:22118705]; cAMP binding inhibits its association with SUR1, regulating assembly of this complex [PMID:12601083, PMID:15561922]. Its membrane localization depends on the N-terminal cAMP-binding domain A, and SNAP-25 engagement couples it to the rapidly releasable granule pool [PMID:19170062, PMID:19509185], while at the fusion site it recruits amisyn and dynamin-1 to restrict and slow fusion pore expansion [PMID:31099751]. In neurons, RAPGEF4 is activated by neuroligin and drives Rap-dependent dendritic spine shrinkage, AMPA receptor removal, and synaptic depression, with autism-associated missense mutations altering its GEF activity and spine morphology [PMID:19734897]; it is also required for electrophysiological maturation of primate prefrontal cortical neurons downstream of CHD8 [PMID:40398411, PMID:37398253]. Beyond these roles it mediates a GLP-1R→Epac2→atrial natriuretic peptide axis in cardiomyocytes [PMID:23542788] and GLP-1R agonist-induced beta-cell autophagy via a Ca2+–calcineurin–TFEB pathway [PMID:34338148]. RAPGEF4 acts as a negative regulator of endothelial migration and tubulogenesis [PMID:17491018, PMID:34593918].","teleology":[{"year":2000,"claim":"Established RAPGEF4 as a direct cAMP target that drives Ca2+-dependent exocytosis independently of PKA, defining a previously unrecognized branch of cAMP signaling.","evidence":"Co-IP/binding to Rim and Rim2 plus reconstituted exocytosis with PKA inhibitor controls","pmids":["11056535"],"confidence":"High","gaps":["Direct Rap1 GEF activity not yet linked to the exocytotic readout here","Full effector complex not yet defined"]},{"year":2001,"claim":"Showed the cAMP-GEFII–Rim2 pathway operates in native beta-cells in parallel with PKA to mediate incretin-potentiated insulin secretion, quantifying the relative contribution of each arm.","evidence":"Antisense knockdown in pancreatic islets with H-89 combinatorial pharmacology","pmids":["11598134"],"confidence":"High","gaps":["Antisense knockdown can have off-target effects","Molecular link between Rim2 binding and secretion not resolved"]},{"year":2001,"claim":"Demonstrated alternative promoter usage generates a liver-specific isoform lacking the first cAMP-binding and DEP domains yet retaining Rap1 GEF activity, separating catalytic activity from cAMP-sensing modules.","evidence":"cDNA cloning, expression mapping, and GEF activity assay","pmids":["11707077"],"confidence":"High","gaps":["Physiological function of the liver isoform not established","Regulation of the truncated isoform unclear"]},{"year":2002,"claim":"Identified Piccolo as the Ca2+-sensing component of the cAMP-GEFII·Rim2 complex, explaining how Ca2+ dependence is conferred on cAMP-induced exocytosis.","evidence":"Co-IP, Ca2+-dependent dimerization assays, antisense knockdown with secretion readout","pmids":["12401793"],"confidence":"High","gaps":["Stoichiometry of the complex not defined","Direct demonstration of Ca2+ sensing in vivo limited"]},{"year":2003,"claim":"Resolved the full beta-cell signaling complex (cAMP-GEFII, Rim2, Piccolo, SUR1, L-type VDCC) and the SUR1–NBF1 interaction, showing how ATP, cAMP, and Ca2+ signals are physically integrated at the exocytotic site.","evidence":"Co-IP, immunolocalization, SUR1-knockout electrophysiology, dominant-negative Rim2","pmids":["12601083","14660679"],"confidence":"High","gaps":["Spatial organization of the complex at single-granule resolution unresolved","Mechanism of cAMP-dependent Cl- influx incompletely defined"]},{"year":2004,"claim":"Demonstrated cAMP regulates the assembly state of the KATP/cAMP-GEFII/Piccolo/VDCC complex, providing a switch mechanism whereby cAMP binding releases RAPGEF4 from SUR1.","evidence":"Co-IP and pull-down with 8-bromo-cAMP and ATP perturbations","pmids":["15561922"],"confidence":"Medium","gaps":["Biochemical assays only; in-cell dynamics of assembly not shown","Single lab"]},{"year":2003,"claim":"Linked RAPGEF4 to GLP-1-stimulated ryanodine receptor Ca2+ release and mitochondrial ATP synthesis, broadening its role beyond direct exocytic machinery to intracellular Ca2+ mobilization.","evidence":"Dominant-negative mutant and pharmacological inhibitors with mitochondrial ATP/Ca2+ imaging in MIN6 cells","pmids":["12410638"],"confidence":"Medium","gaps":["Dominant-negative specificity not orthogonally confirmed","Single cell line and lab"]},{"year":2005,"claim":"Generalized the PKA-independent Epac2 exocytic arm to neuroendocrine melanotrophs and assigned it to a distinct kinetic component of secretion.","evidence":"Patch-clamp capacitance in pituitary slices with Epac- and PKA-selective agonists","pmids":["15994184"],"confidence":"Medium","gaps":["Molecular effectors in melanotrophs not identified","Single lab"]},{"year":2009,"claim":"Mapped RAPGEF4 membrane targeting to cAMP-binding domain A and showed this localization is required for secretory function, explaining isoform-specific activity.","evidence":"Domain deletion/splice variant analysis, membrane-targeting rescue, secretion assays, KO mice","pmids":["19170062"],"confidence":"High","gaps":["Membrane lipid/protein anchor for domain A not identified"]},{"year":2009,"claim":"Connected RAPGEF4 to the SNARE machinery via SNAP-25, defining its requirement for cAMP potentiation of the immediately releasable granule pool.","evidence":"Protein-binding assays plus capacitance measurements with truncated SNAP-25/BoNT/A in INS-1 cells","pmids":["19509185"],"confidence":"Medium","gaps":["Direct vs Rim2-bridged SNAP-25 binding not resolved","Single lab"]},{"year":2009,"claim":"Defined a neuronal role: neuroligin-activated RAPGEF4 drives Rap-dependent spine shrinkage and synaptic depression, with autism mutations perturbing its GEF activity and synaptic output.","evidence":"Activation/inhibition in cortical neurons, spine imaging, electrophysiology, neuroligin Co-IP, mutant GEF assays","pmids":["19734897"],"confidence":"High","gaps":["Rap effectors mediating spine remodeling not fully mapped","In vivo behavioral consequence of mutants not tested here"]},{"year":2012,"claim":"Established that sulfonylureas (except gliclazide) act partly through Epac2/Rap1, defining RAPGEF4 as a pharmacological target of these drugs.","evidence":"Pharmacological comparison of sulfonylureas with Epac2/Rap1 activation assays","pmids":["22118705"],"confidence":"Medium","gaps":["Review-level synthesis; direct binding mode of each drug to Epac2 not detailed","Single group"]},{"year":2013,"claim":"Extended RAPGEF4 to cardiac physiology, defining a GLP-1R→Epac2→ANP axis that lowers blood pressure.","evidence":"Membrane translocation imaging and multiple knockout mouse lines with ANP and vasorelaxation readouts","pmids":["23542788"],"confidence":"High","gaps":["Rap effector coupling to ANP granule release in cardiomyocytes not detailed"]},{"year":2013,"claim":"Demonstrated a developmental/endocytic role for Rapgef4 downstream of Gnas/cAMP in renal proximal tubule growth and transport.","evidence":"Morpholino knockdown in Xenopus and agonist treatment with albumin uptake assays in human tubular cells","pmids":["23352791"],"confidence":"Medium","gaps":["Downstream Rap effectors in tubular cells unidentified","Morpholino off-target effects"]},{"year":2014,"claim":"Identified an EPAC2→CALR→LIF/PTGS2 axis in endometrial gland epithelium, expanding RAPGEF4 to reproductive tissue gene regulation.","evidence":"siRNA knockdown of EPAC2 and CALR with selective cAMP analogs and senescence assays","pmids":["25378661"],"confidence":"Medium","gaps":["Mechanism linking EPAC2 to CALR expression unknown","Single lab"]},{"year":2015,"claim":"Provided structural basis for cAMP-induced activation, showing dynamic conformational changes accompany cAMP sensing and Rap GEF activity.","evidence":"Crystallographic analysis (review synthesizing prior structures)","pmids":["26390815"],"confidence":"Medium","gaps":["Structures of full effector complex not resolved","Review format"]},{"year":2015,"claim":"Showed adenylyl-cyclase isoform selectivity (AC6 not AC7) routes PACAP-driven cAMP to Epac2/p38 signaling, illustrating compartmentalized cAMP signaling through RAPGEF4.","evidence":"shRNA knockdown of AC6/AC7 with phospho-p38 readout and cholesterol depletion in PC12 cells","pmids":["25769305"],"confidence":"Medium","gaps":["Direct Epac2-p38 coupling mechanism not defined","Single lab"]},{"year":2016,"claim":"Implicated RAPGEF4 in mood regulation and hippocampal neurogenesis via knockout behavioral phenotypes rescuable by SSRI.","evidence":"Epac2-knockout mouse behavioral tests, neurogenesis assay, fluoxetine treatment","pmids":["27598965"],"confidence":"Medium","gaps":["Molecular pathway linking Epac2 to neurogenesis unresolved","Single lab"]},{"year":2019,"claim":"Defined a fusion-pore-restricting function: RAPGEF4 acutely recruits amisyn and dynamin-1 to slow pore expansion, revealing control of the kinetics of granule cargo release.","evidence":"TIRF imaging of fusion pore dynamics in Rapgef4-/- mice with effector recruitment imaging and pharmacology","pmids":["31099751"],"confidence":"High","gaps":["Whether Rap1 GEF activity is required for recruitment not resolved","Direct binding of Epac2 to amisyn/dynamin-1 not biochemically mapped"]},{"year":2021,"claim":"Established a RAPGEF4→Ca2+→calcineurin→TFEB axis driving exendin-4-induced autophagy and beta-cell survival, linking RAPGEF4 to cytoprotective transcriptional programs.","evidence":"siRNA knockdown in INS-1E cells and human islets, TFEB overexpression, db/db mouse exendin-4 treatment","pmids":["34338148"],"confidence":"Medium","gaps":["Step linking Rap1 activation to calcineurin not defined","Single lab"]},{"year":2021,"claim":"Identified EPAC2 as a negative regulator of endothelial tube formation and migration, consistent with its earlier anti-chemotactic role.","evidence":"Reciprocal overexpression and siRNA in HMVECs with Matrigel and migration assays","pmids":["34593918"],"confidence":"Medium","gaps":["Cytoskeletal effector pathway not fully mapped","Single lab"]},{"year":2025,"claim":"Placed RAPGEF4 downstream of CHD8 as required for primate prefrontal cortical neuron electrophysiological maturation, demonstrated by knockdown and rescue.","evidence":"Patch-seq, single-nucleus multiomics, CHD8 knockdown and RAPGEF4 restoration in macaque and human organotypic slices","pmids":["40398411","37398253"],"confidence":"High","gaps":["Molecular targets driving membrane potential/Na+ current changes not identified","Whether GEF activity mediates maturation untested"]},{"year":2025,"claim":"Showed hepatic EPAC2 is dispensable for the GCGR→GNAS→PKA liver-alpha-cell loop, sharpening the boundary between PKA-dependent and Epac2-dependent cAMP responses.","evidence":"siRNA/ASO knockdown of GCGR/GNAS/PKA/EPAC2 in mouse liver with metabolic readouts (negative result for EPAC2)","pmids":["40095004"],"confidence":"Medium","gaps":["Negative result; possible compensation or incomplete knockdown not excluded","Single lab"]},{"year":2026,"claim":"Identified EPAC2 upregulation in fragile X model cortex and showed pharmacological antagonism rescues circuit and behavioral phenotypes, nominating it as a therapeutic target.","evidence":"Cell-type-specific translatomics, EPAC2 antagonist treatment in Fmr1-KO mice, circuit electrophysiology and behavior","pmids":["42155452"],"confidence":"Medium","gaps":["Mechanism linking EPAC2 upregulation to circuit dysfunction not defined","Single lab"]},{"year":null,"claim":"How RAPGEF4 GEF/Rap1 activity is mechanistically partitioned among its many tissue-specific outputs (exocytosis, fusion-pore control, spine remodeling, autophagy, neuronal maturation) remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified model linking Rap1 effector choice to distinct cellular outputs","Structures of full physiological effector complexes not solved","Whether catalytic GEF activity is required for all phenotypes not systematically tested"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140299","term_label":"molecular sensor activity","supporting_discovery_ids":[0,17]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[2,11,9]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[0,17]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[6,10,14]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[10]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,17]},{"term_id":"R-HSA-5653656","term_label":"Vesicle-mediated transport","supporting_discovery_ids":[0,6,20]},{"term_id":"R-HSA-9612973","term_label":"Autophagy","supporting_discovery_ids":[21]}],"complexes":["cAMP-GEFII·Rim2·Piccolo·SUR1·L-type VDCC exocytotic complex"],"partners":["RIMS2","PCLO","ABCC8","CACNA1C","SNAP25","NLGN1","DNM1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q8WZA2","full_name":"Rap guanine nucleotide exchange factor 4","aliases":["Exchange factor directly activated by cAMP 2","Exchange protein directly activated by cAMP 2","EPAC 2","cAMP-regulated guanine nucleotide exchange factor II","cAMP-GEFII"],"length_aa":1011,"mass_kda":115.5,"function":"Guanine nucleotide exchange factor (GEF) for RAP1A, RAP1B and RAP2A small GTPases that is activated by binding cAMP. Does not seem to activate RAB3A. Involved in cAMP-dependent, PKA-independent exocytosis through interaction with RIMS2 (By similarity)","subcellular_location":"Cytoplasm; Membrane","url":"https://www.uniprot.org/uniprotkb/Q8WZA2/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/RAPGEF4","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/RAPGEF4","total_profiled":1310},"omim":[{"mim_id":"606058","title":"RAP GUANINE NUCLEOTIDE EXCHANGE FACTOR; RAPGEF4","url":"https://www.omim.org/entry/606058"},{"mim_id":"606057","title":"RAP GUANINE NUCLEOTIDE EXCHANGE FACTOR 3; RAPGEF3","url":"https://www.omim.org/entry/606057"},{"mim_id":"209850","title":"AUTISM","url":"https://www.omim.org/entry/209850"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Focal adhesion sites","reliability":"Approved"},{"location":"Plasma membrane","reliability":"Additional"},{"location":"Basal body","reliability":"Additional"},{"location":"Cytosol","reliability":"Additional"},{"location":"Mid piece","reliability":"Additional"}],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"brain","ntpm":272.2}],"url":"https://www.proteinatlas.org/search/RAPGEF4"},"hgnc":{"alias_symbol":["cAMP-GEFII","CGEF2"],"prev_symbol":[]},"alphafold":{"accession":"Q8WZA2","domains":[{"cath_id":"2.60.120.10","chopping":"7-154","consensus_level":"high","plddt":87.7264,"start":7,"end":154},{"cath_id":"1.10.10.10","chopping":"200-322","consensus_level":"high","plddt":93.0767,"start":200,"end":322},{"cath_id":"2.60.120.10","chopping":"343-456","consensus_level":"medium","plddt":87.0005,"start":343,"end":456},{"cath_id":"1.20.870.10","chopping":"470-481_497-639","consensus_level":"medium","plddt":88.1908,"start":470,"end":639},{"cath_id":"3.10.20.90","chopping":"646-756","consensus_level":"medium","plddt":89.4032,"start":646,"end":756},{"cath_id":"1.10.840.10","chopping":"763-1005","consensus_level":"high","plddt":93.3818,"start":763,"end":1005}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q8WZA2","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q8WZA2-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q8WZA2-F1-predicted_aligned_error_v6.png","plddt_mean":87.0},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=RAPGEF4","jax_strain_url":"https://www.jax.org/strain/search?query=RAPGEF4"},"sequence":{"accession":"Q8WZA2","fasta_url":"https://rest.uniprot.org/uniprotkb/Q8WZA2.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q8WZA2/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q8WZA2"}},"corpus_meta":[{"pmid":"23542788","id":"PMC_23542788","title":"GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure.","date":"2013","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/23542788","citation_count":417,"is_preprint":false},{"pmid":"11056535","id":"PMC_11056535","title":"cAMP-GEFII is a direct target of cAMP in regulated exocytosis.","date":"2000","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/11056535","citation_count":387,"is_preprint":false},{"pmid":"11598134","id":"PMC_11598134","title":"Critical role of cAMP-GEFII--Rim2 complex in incretin-potentiated insulin secretion.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11598134","citation_count":290,"is_preprint":false},{"pmid":"12601083","id":"PMC_12601083","title":"SUR1 regulates PKA-independent cAMP-induced granule priming in mouse pancreatic B-cells.","date":"2003","source":"The Journal of general physiology","url":"https://pubmed.ncbi.nlm.nih.gov/12601083","citation_count":212,"is_preprint":false},{"pmid":"12410638","id":"PMC_12410638","title":"Glucagon-like peptide-1 mobilizes intracellular Ca2+ and stimulates mitochondrial ATP synthesis in pancreatic MIN6 beta-cells.","date":"2003","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/12410638","citation_count":177,"is_preprint":false},{"pmid":"12401793","id":"PMC_12401793","title":"Piccolo, a Ca2+ sensor in pancreatic beta-cells. Involvement of cAMP-GEFII.Rim2. Piccolo complex in cAMP-dependent exocytosis.","date":"2002","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12401793","citation_count":167,"is_preprint":false},{"pmid":"14660679","id":"PMC_14660679","title":"Interaction of ATP sensor, cAMP sensor, Ca2+ sensor, and voltage-dependent Ca2+ channel in insulin granule exocytosis.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/14660679","citation_count":142,"is_preprint":false},{"pmid":"19734897","id":"PMC_19734897","title":"Epac2 induces synapse remodeling and depression and its disease-associated forms alter spines.","date":"2009","source":"Nature neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/19734897","citation_count":133,"is_preprint":false},{"pmid":"14593429","id":"PMC_14593429","title":"Screening of nine candidate genes for autism on chromosome 2q reveals rare nonsynonymous variants in the cAMP-GEFII gene.","date":"2003","source":"Molecular psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/14593429","citation_count":96,"is_preprint":false},{"pmid":"26295306","id":"PMC_26295306","title":"Combined expressional analysis, bioinformatics and targeted proteomics identify new potential therapeutic targets in glioblastoma stem cells.","date":"2015","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/26295306","citation_count":88,"is_preprint":false},{"pmid":"19170062","id":"PMC_19170062","title":"Critical role of the N-terminal cyclic AMP-binding domain of Epac2 in its subcellular localization and function.","date":"2009","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/19170062","citation_count":82,"is_preprint":false},{"pmid":"26474971","id":"PMC_26474971","title":"A genome-wide approach to link genotype to clinical outcome by utilizing next generation sequencing and gene chip data of 6,697 breast cancer patients.","date":"2015","source":"Genome medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26474971","citation_count":70,"is_preprint":false},{"pmid":"29986310","id":"PMC_29986310","title":"Folic acid supplementation alters the DNA methylation profile and improves insulin resistance in high-fat-diet-fed mice.","date":"2018","source":"The Journal of nutritional biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/29986310","citation_count":53,"is_preprint":false},{"pmid":"11707077","id":"PMC_11707077","title":"Characterization of the gene EPAC2: structure, chromosomal localization, tissue expression, and identification of the liver-specific isoform.","date":"2001","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/11707077","citation_count":52,"is_preprint":false},{"pmid":"17491018","id":"PMC_17491018","title":"Anthrax edema toxin inhibits endothelial cell chemotaxis via Epac and Rap1.","date":"2007","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17491018","citation_count":52,"is_preprint":false},{"pmid":"15561922","id":"PMC_15561922","title":"Integration of ATP, cAMP, and Ca2+ signals in insulin granule exocytosis.","date":"2004","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/15561922","citation_count":50,"is_preprint":false},{"pmid":"15994184","id":"PMC_15994184","title":"cAMP increases Ca2+-dependent exocytosis through both PKA and Epac2 in mouse melanotrophs from pituitary tissue slices.","date":"2005","source":"The Journal of physiology","url":"https://pubmed.ncbi.nlm.nih.gov/15994184","citation_count":50,"is_preprint":false},{"pmid":"22118705","id":"PMC_22118705","title":"Treating diabetes today: a matter of selectivity of sulphonylureas.","date":"2012","source":"Diabetes, obesity & metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/22118705","citation_count":48,"is_preprint":false},{"pmid":"26390815","id":"PMC_26390815","title":"Structure and functional roles of Epac2 (Rapgef4).","date":"2015","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/26390815","citation_count":47,"is_preprint":false},{"pmid":"24006282","id":"PMC_24006282","title":"Signaling in sperm: toward a molecular understanding of the acquisition of sperm motility in the mouse epididymis.","date":"2013","source":"Biology of reproduction","url":"https://pubmed.ncbi.nlm.nih.gov/24006282","citation_count":39,"is_preprint":false},{"pmid":"31099751","id":"PMC_31099751","title":"Fusion pore regulation by cAMP/Epac2 controls cargo release during insulin exocytosis.","date":"2019","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/31099751","citation_count":38,"is_preprint":false},{"pmid":"27598965","id":"PMC_27598965","title":"Anxiety and depression with neurogenesis defects in exchange protein directly activated by cAMP 2-deficient mice are ameliorated by a selective serotonin reuptake inhibitor, Prozac.","date":"2016","source":"Translational psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/27598965","citation_count":38,"is_preprint":false},{"pmid":"19509185","id":"PMC_19509185","title":"Truncation of SNAP-25 reduces the stimulatory action of cAMP on rapid exocytosis in insulin-secreting cells.","date":"2009","source":"American journal of physiology. Endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/19509185","citation_count":37,"is_preprint":false},{"pmid":"32800727","id":"PMC_32800727","title":"Two-stage Study of Familial Prostate Cancer by Whole-exome Sequencing and Custom Capture Identifies 10 Novel Genes Associated with the Risk of Prostate Cancer.","date":"2020","source":"European urology","url":"https://pubmed.ncbi.nlm.nih.gov/32800727","citation_count":37,"is_preprint":false},{"pmid":"25813215","id":"PMC_25813215","title":"Orexin A regulates plasma insulin and leptin levels in a time-dependent manner following a glucose load in mice.","date":"2015","source":"Diabetologia","url":"https://pubmed.ncbi.nlm.nih.gov/25813215","citation_count":36,"is_preprint":false},{"pmid":"34338148","id":"PMC_34338148","title":"Exendin-4 stimulates autophagy in pancreatic β-cells via the RAPGEF/EPAC-Ca2+-PPP3/calcineurin-TFEB axis.","date":"2021","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/34338148","citation_count":32,"is_preprint":false},{"pmid":"21471298","id":"PMC_21471298","title":"Guanine-nucleotide exchange factors (RAPGEF3/RAPGEF4) induce sperm membrane depolarization and acrosomal exocytosis in capacitated stallion sperm.","date":"2011","source":"Biology of reproduction","url":"https://pubmed.ncbi.nlm.nih.gov/21471298","citation_count":31,"is_preprint":false},{"pmid":"25378661","id":"PMC_25378661","title":"EPAC2-mediated calreticulin regulates LIF and COX2 expression in human endometrial glandular cells.","date":"2014","source":"Journal of molecular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/25378661","citation_count":23,"is_preprint":false},{"pmid":"37800580","id":"PMC_37800580","title":"Function of m5C RNA methyltransferase NOP2 in high-grade serous ovarian cancer.","date":"2023","source":"Cancer biology & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/37800580","citation_count":22,"is_preprint":false},{"pmid":"27379015","id":"PMC_27379015","title":"Role of EPAC in cAMP-Mediated Actions in Adrenocortical Cells.","date":"2016","source":"Frontiers in endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/27379015","citation_count":17,"is_preprint":false},{"pmid":"40398411","id":"PMC_40398411","title":"Multimodal analyses reveal genes driving electrophysiological maturation of neurons in the primate prefrontal cortex.","date":"2025","source":"Neuron","url":"https://pubmed.ncbi.nlm.nih.gov/40398411","citation_count":12,"is_preprint":false},{"pmid":"25769305","id":"PMC_25769305","title":"Cyclic Adenosine 3',5'-Monophosphate Elevation and Biological Signaling through a Secretin Family Gs-Coupled G Protein-Coupled Receptor Are Restricted to a Single Adenylate Cyclase Isoform.","date":"2015","source":"Molecular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/25769305","citation_count":11,"is_preprint":false},{"pmid":"32395202","id":"PMC_32395202","title":"EPAC2: A new and promising protein for glioma pathogenesis and therapy.","date":"2020","source":"Oncology reviews","url":"https://pubmed.ncbi.nlm.nih.gov/32395202","citation_count":8,"is_preprint":false},{"pmid":"35834616","id":"PMC_35834616","title":"EPAC Regulates Melanoma Growth by Stimulating mTORC1 Signaling and Loss of EPAC Signaling Dependence Correlates with Melanoma Progression.","date":"2022","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/35834616","citation_count":8,"is_preprint":false},{"pmid":"23352791","id":"PMC_23352791","title":"Regulation of G-protein signaling via Gnas is required to regulate proximal tubular growth in the Xenopus pronephros.","date":"2013","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/23352791","citation_count":6,"is_preprint":false},{"pmid":"20659433","id":"PMC_20659433","title":"Over-expression of the DCLK gene transcript CARP decreases CA3/CA1 network excitability.","date":"2010","source":"Brain research","url":"https://pubmed.ncbi.nlm.nih.gov/20659433","citation_count":6,"is_preprint":false},{"pmid":"34516037","id":"PMC_34516037","title":"Investigation of Diagnostic Biomarkers for Osteoporosis Based on Differentially Expressed Gene Profile with QCT and mDixon-Quant Techniques.","date":"2021","source":"Orthopaedic surgery","url":"https://pubmed.ncbi.nlm.nih.gov/34516037","citation_count":5,"is_preprint":false},{"pmid":"16412482","id":"PMC_16412482","title":"Depolarization and Ca(2+) down regulate CB1 receptors and CB1-mediated signaling in cerebellar granule neurons.","date":"2006","source":"Neuropharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/16412482","citation_count":5,"is_preprint":false},{"pmid":"34609028","id":"PMC_34609028","title":"Gene polymorphisms of insulin secretion signaling pathway associated with clopidogrel resistance in Han Chinese population.","date":"2021","source":"Journal of clinical laboratory analysis","url":"https://pubmed.ncbi.nlm.nih.gov/34609028","citation_count":5,"is_preprint":false},{"pmid":"40095004","id":"PMC_40095004","title":"Hepatic PKA Mediates Liver and Pancreatic α-Cell Cross Talk.","date":"2025","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/40095004","citation_count":4,"is_preprint":false},{"pmid":"35567499","id":"PMC_35567499","title":"Deciphering complex rearrangements at the breakpoint of an apparently balanced reciprocal translocation t(4:18)(q31;q11.2)dn and at a cryptic deletion: Further evidence of TLL1 as a causative gene for atrial septal defect.","date":"2022","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/35567499","citation_count":4,"is_preprint":false},{"pmid":"37398253","id":"PMC_37398253","title":"Multimodal analyses reveal genes driving electrophysiological maturation of neurons in the primate prefrontal cortex.","date":"2024","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/37398253","citation_count":3,"is_preprint":false},{"pmid":"40170064","id":"PMC_40170064","title":"Downregulation of FASN in granulosa cells and its impact on ovulatory dysfunction in PCOS.","date":"2025","source":"Journal of ovarian research","url":"https://pubmed.ncbi.nlm.nih.gov/40170064","citation_count":3,"is_preprint":false},{"pmid":"34593918","id":"PMC_34593918","title":"EPAC2 acts as a negative regulator in Matrigel-driven tubulogenesis of human microvascular endothelial cells.","date":"2021","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/34593918","citation_count":3,"is_preprint":false},{"pmid":"40025369","id":"PMC_40025369","title":"Sex-specific molecular drivers of cardiac fibrosis in aging hearts.","date":"2025","source":"GeroScience","url":"https://pubmed.ncbi.nlm.nih.gov/40025369","citation_count":2,"is_preprint":false},{"pmid":"41311249","id":"PMC_41311249","title":"Breast Cancer-Secreted DPP3 Promotes Lung Metastasis by Remodelling the Vascular Niche in Lung via the Rap1 Signalling Pathway.","date":"2025","source":"Journal of extracellular vesicles","url":"https://pubmed.ncbi.nlm.nih.gov/41311249","citation_count":2,"is_preprint":false},{"pmid":"32905835","id":"PMC_32905835","title":"The Epac2 coding gene (RAPGEF4) rs3769219 polymorphism is associated with protection against major depressive disorder in the Chinese Han population.","date":"2020","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/32905835","citation_count":0,"is_preprint":false},{"pmid":"41123461","id":"PMC_41123461","title":"Analysis of copy number variations and selection signatures using whole-genome sequencing data from 16 Chinese duck breeds.","date":"2025","source":"British poultry science","url":"https://pubmed.ncbi.nlm.nih.gov/41123461","citation_count":0,"is_preprint":false},{"pmid":"42155452","id":"PMC_42155452","title":"Translatome profiling reveals opposing alterations in inhibitory and excitatory neurons of fragile X mice and identifies EPAC2 as a therapeutic target.","date":"2026","source":"Neuron","url":"https://pubmed.ncbi.nlm.nih.gov/42155452","citation_count":0,"is_preprint":false},{"pmid":"42184924","id":"PMC_42184924","title":"Targeting dysregulated glycolysis in type 2 diabetic osteoporosis: Identification of a diagnostic gene signature and therapeutic validation of calcifediol.","date":"2026","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/42184924","citation_count":0,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":28010,"output_tokens":6918,"usd":0.0939,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":16163,"output_tokens":6448,"usd":0.121008,"stage2_stop_reason":"end_turn"},"total_usd":0.214908,"stage1_batch_id":"msgbatch_01CNoDbkChHEkgrJnL7BwtGJ","stage2_batch_id":"msgbatch_016Y4x9E9Wg5VQDANj9quSQD","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2000,\n      \"finding\": \"cAMP-GEFII (RAPGEF4) directly binds to Rim (Rab3-interacting molecule) and a new isoform Rim2, and mediates cAMP-induced, Ca2+-dependent exocytosis that is not blocked by PKA inhibitors, establishing it as a direct cAMP target in regulated exocytosis via a PKA-independent mechanism.\",\n      \"method\": \"Co-immunoprecipitation/binding assays, reconstituted exocytosis system, PKA inhibitor pharmacology\",\n      \"journal\": \"Nature cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — binding interaction demonstrated with functional reconstitution, PKA-independent mechanism established with inhibitor controls, foundational study replicated by multiple subsequent labs\",\n      \"pmids\": [\"11056535\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"The cAMP-GEFII–Rim2 pathway mediates PKA-independent incretin-potentiated insulin secretion in native pancreatic beta-cells; antisense knockdown of cAMP-GEFII alone inhibited incretin-potentiated secretion ~50%, and combined with PKA inhibitor H-89 inhibited ~80–90%, demonstrating both pathways act in parallel.\",\n      \"method\": \"Antisense oligodeoxynucleotide knockdown in pancreatic islets, insulin secretion assays, PKA inhibitor (H-89) pharmacology\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — loss-of-function in native tissue with defined secretory phenotype, replicated in subsequent studies, two orthogonal inhibition strategies used\",\n      \"pmids\": [\"11598134\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"The EPAC2/cAMP-GEFII gene encodes a liver-specific isoform (79 kDa) initiated from exon 10, lacking the first cAMP-binding domain and DEP domain, that retains GEF activity toward Rap1, demonstrating alternative promoter usage creates functionally distinct isoforms.\",\n      \"method\": \"cDNA cloning, primer extension, RT-PCR, in situ hybridization, immunoblot, GEF activity assay\",\n      \"journal\": \"Genomics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — multiple orthogonal molecular methods (cloning, expression mapping, enzymatic assay) in a single study\",\n      \"pmids\": [\"11707077\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"cAMP-GEFII forms a complex with Rim2 and Piccolo; Piccolo acts as a Ca2+-sensor by forming Ca2+-dependent homodimers and heterodimers with Rim2, and antisense knockdown of Piccolo inhibits cAMP analog-induced insulin secretion, implicating the cAMP-GEFII·Rim2·Piccolo complex in cAMP-induced exocytosis.\",\n      \"method\": \"Co-immunoprecipitation, dimerization assays (Ca2+-dependent), antisense oligodeoxynucleotide knockdown in pancreatic islets, insulin secretion assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal binding assays with functional knockdown validation, replicated across multiple subsequent studies\",\n      \"pmids\": [\"12401793\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"SUR1 (sulfonylurea receptor 1, a subunit of the KATP channel) physically interacts with cAMP-GEFII through its nucleotide-binding fold 1 (NBF1); this interaction is decreased by high concentrations of cAMP. SUR1-deficient beta-cells completely lack the PKA-independent component of cAMP-stimulated exocytosis, and this defect is associated with impaired cAMP-dependent Cl- influx into granules required for granule priming.\",\n      \"method\": \"Co-immunoprecipitation, antisense knockdown, capacitance measurements in SUR1-knockout mouse beta-cells, insulin release assays\",\n      \"journal\": \"The Journal of general physiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — genetic knockout combined with electrophysiology and interaction assays, multiple orthogonal methods\",\n      \"pmids\": [\"12601083\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"cAMP-GEFII mediates GLP-1-stimulated ryanodine receptor-dependent Ca2+ release from intracellular stores and subsequent mitochondrial ATP synthesis in MIN6 beta-cells; a dominant-negative form of cAMP-GEFII (G114E,G422D) blocked this xestospongin C-insensitive (RyR-mediated) component of [ATP]m increase.\",\n      \"method\": \"Dominant-negative mutant expression, pharmacological inhibitors (xestospongin C, ryanodine, H-89), mitochondrial ATP/Ca2+ imaging in MIN6 cells\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — dominant-negative mutagenesis with functional readout in a single lab, two orthogonal inhibitor strategies\",\n      \"pmids\": [\"12410638\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"cAMP-GEFII, Rim2, Piccolo, SUR1, and L-type VDCC (alpha1 1.2 subunit) form an integrated signaling complex in pancreatic beta-cells: SUR1 interacts with cAMP-GEFII via NBF1; Rim2 interacts with cAMP-GEFII and requires its Rab3-binding region for plasma membrane localization; Piccolo and Rim2 both bind directly to the VDCC alpha1 1.2 subunit. This complex integrates ATP, cAMP, and Ca2+ signals for insulin granule exocytosis.\",\n      \"method\": \"Co-immunoprecipitation, immunolocalization in MIN6 cells, dominant-negative Rim2 overexpression with exocytosis measurements\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple binary and multiprotein interactions demonstrated, dominant-negative functional validation, consistent with prior and subsequent studies\",\n      \"pmids\": [\"14660679\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"SUR1, cAMP-GEFII, and Piccolo can form a trimeric complex; interaction of cAMP-GEFII with SUR1 is inhibited by 8-bromo-cAMP (but not by ATP), and this inhibition persists in the presence of ATP, indicating cAMP regulates the assembly state of the KATP/cAMP-GEFII/Piccolo/VDCC complex.\",\n      \"method\": \"Co-immunoprecipitation with cAMP analog treatments, pull-down assays\",\n      \"journal\": \"Diabetes\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — biochemical interaction assays with pharmacological perturbation, single lab but consistent with prior structural complex studies\",\n      \"pmids\": [\"15561922\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"In mouse melanotrophs, cAMP stimulates exocytosis through both PKA-dependent and Epac2/cAMP-GEFII-dependent pathways; the 8-pCPT-2Me-cAMP (Epac-selective agonist) specifically potentiated the linear (rapidly releasable) component of exocytosis, while PKA inhibition abolished the threshold component, demonstrating separable roles.\",\n      \"method\": \"Whole-cell patch-clamp capacitance measurements in pituitary tissue slices, pharmacological dissection with Epac-selective agonist, PKA inhibitors (H-89, Rp-cAMPS), and PKA-selective agonist (6-Phe-cAMP)\",\n      \"journal\": \"The Journal of physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — electrophysiological measurements with selective pharmacological tools in native tissue, single lab\",\n      \"pmids\": [\"15994184\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Anthrax edema toxin-generated cAMP inhibits endothelial cell chemotaxis via Epac2 (RAPGEF4) and its substrate Rap1; activated Epac or Rap1 induces cytoskeletal changes and blocks chemotaxis in human microvascular endothelial cells, and ET induces transcription of Epac2/RAPGEF4.\",\n      \"method\": \"Activated Epac/Rap1 overexpression, endothelial cell chemotaxis assays, cytoskeletal imaging\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gain-of-function with defined morphological and chemotaxis phenotype, single lab, two orthogonal interventions (Epac and Rap1 activation)\",\n      \"pmids\": [\"17491018\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"The N-terminal cAMP-binding domain A of Epac2A is critical for its plasma membrane localization in MIN6 cells; Epac2B (a splice variant lacking this domain) localizes to the cytoplasm and fails to potentiate hormone secretion, whereas adding a membrane-targeting signal to Epac2B restores its secretory function.\",\n      \"method\": \"Immunocytochemistry, domain deletion/splice variant analysis, membrane-targeting signal fusion, insulin secretion assay in MIN6 cells, characterization of Epac2-knockout mice\",\n      \"journal\": \"Journal of cellular physiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — domain mapping with functional rescue experiment, multiple orthogonal approaches (localization + secretion + membrane targeting), supported by KO mouse model\",\n      \"pmids\": [\"19170062\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Epac2 (RAPGEF4) activation in cortical neurons induces spine shrinkage, increases spine motility, removes GluR2/3-containing AMPA receptors from synapses, and depresses excitatory transmission; inhibition of Epac2 promotes spine enlargement and stabilization. Epac2 interaction with neuroligin promotes membrane recruitment and enhances its GEF activity. Autism-associated rare missense mutations in EPAC2 alter basal and neuroligin-stimulated GEF activity, dendritic Rap signaling, synaptic protein distribution, and spine morphology.\",\n      \"method\": \"Epac2 activation/inhibition in cultured rat cortical neurons, live imaging of spine dynamics, electrophysiology, GluR2 immunostaining, neuroligin co-immunoprecipitation, GEF activity assays for autism-associated mutants\",\n      \"journal\": \"Nature neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — multiple orthogonal methods (imaging, electrophysiology, biochemistry, mutagenesis), neuroligin interaction validated by Co-IP, GEF activity directly measured for mutants\",\n      \"pmids\": [\"19734897\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"SNAP-25 physically interacts with both cAMP-GEFII and RIM2; truncation of SNAP-25 C-terminus abolishes cAMP potentiation of rapid exocytosis from the immediately releasable pool (the cAMP-GEFII/PKA-independent pathway) in insulin-secreting cells, while reserve pool mobilization by cAMP is preserved.\",\n      \"method\": \"Capacitance measurements, protein-binding assays, Western blot, INS-1 cells overexpressing truncated SNAP-25 or BoNT/A\",\n      \"journal\": \"American journal of physiology. Endocrinology and metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — interaction assay combined with functional exocytosis measurements, single lab with two orthogonal tools (truncation and toxin)\",\n      \"pmids\": [\"19509185\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Sulfonylureas (except gliclazide) activate Epac2/Rap1 signaling to promote insulin granule exocytosis; Epac2 is required for the full insulinotropic effect of sulfonylureas as well as for incretin-potentiated insulin secretion; gliclazide uniquely does not activate Epac2 and is specific to KATP channel inhibition.\",\n      \"method\": \"Pharmacological comparison of sulfonylureas, Epac2-dependent signaling assays, Rap1 activation assays\",\n      \"journal\": \"Diabetes, obesity & metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — review synthesizing experimental findings from prior studies with mechanistic specificity on drug-target selectivity; single group, multiple experimental approaches referenced\",\n      \"pmids\": [\"22118705\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"GLP-1 receptor activation promotes translocation of Epac2 (RAPGEF4) to the cardiomyocyte membrane; Epac2 deficiency eliminates GLP-1R-dependent stimulation of atrial natriuretic peptide (ANP) secretion from cardiac atria, establishing a GLP-1R→Epac2→ANP axis that reduces blood pressure.\",\n      \"method\": \"Epac2 membrane translocation imaging, Epac2-knockout mice (ANP secretion assays), conditioned medium aortic ring relaxation assay, GLP-1R-knockout and Nppa-knockout mice\",\n      \"journal\": \"Nature medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic knockout with defined physiological phenotype, membrane translocation imaging, multiple KO lines used to dissect pathway\",\n      \"pmids\": [\"23542788\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"In Xenopus pronephros, Rapgef4-dependent signaling downstream of Gnas/cAMP controls exo- and endocytosis and regulates proximal tubular growth; a Rapgef4-specific agonist in a human proximal tubular cell line increased albumin uptake and decreased secretion, phenocopying cholera toxin effects.\",\n      \"method\": \"Antisense morpholino knockdown in Xenopus embryos, pharmacological agonist/antagonist treatments, FITC-albumin uptake/secretion assays in human proximal tubular cells\",\n      \"journal\": \"Developmental biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — morpholino loss-of-function with defined tubular phenotype and pharmacological validation in human cell line, single lab\",\n      \"pmids\": [\"23352791\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"EPAC2 (RAPGEF4) in endometrial glandular epithelial cells regulates calreticulin (CALR) protein and mRNA expression; EPAC2 or CALR knockdown suppresses PKA-agonist-induced LIF and COX2 (PTGS2) expression and PGE2 secretion, and increases cellular senescence markers, establishing an EPAC2→CALR→LIF/PTGS2 axis in endometrial gland function.\",\n      \"method\": \"siRNA knockdown of EPAC2 and CALR in EM1 cells, EPAC-selective and PKA-selective cAMP analogs, gene/protein expression analysis, senescence-associated beta-galactosidase assay\",\n      \"journal\": \"Journal of molecular endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA knockdown with pathway dissection using selective cAMP analogs, single lab, two orthogonal knockdowns\",\n      \"pmids\": [\"25378661\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Crystallographic analysis of Epac2 revealed that cAMP-induced activation is accompanied by dynamic structural changes, and the protein functions as a direct cAMP sensor with GEF activity toward Rap.\",\n      \"method\": \"Crystallographic analysis (structural review synthesizing prior crystal structures)\",\n      \"journal\": \"Gene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — review citing crystallographic data, structural basis for cAMP-induced conformational activation established; treated as Tier 1 for structural finding but Moderate given review format\",\n      \"pmids\": [\"26390815\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"PACAP-38 activation of Epac2/Rapgef4 downstream signaling (p38 phosphorylation) requires AC6 but not AC7; this selectivity depends on the vicinal constraint of PAC1 receptor and AC6, while coupling of Epac2 to p38 determines how cAMP is parcellated to physiological responses in neuroendocrine PC12 cells.\",\n      \"method\": \"lentiviral shRNA knockdown of AC6 and AC7, PACAP-38 stimulation, phospho-p38 and phospho-CREB immunoblotting, methyl-beta-cyclodextrin cholesterol depletion\",\n      \"journal\": \"Molecular pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — selective knockdown with defined signaling readout, two orthogonal approaches (genetic and pharmacological disruption of membrane microdomains), single lab\",\n      \"pmids\": [\"25769305\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Epac2-knockout mice exhibit anxiety, depression, learning and memory deficits, and impaired hippocampal cell proliferation; Prozac (fluoxetine, SSRI) treatment ameliorates these phenotypes in Epac2-/- mice, establishing Epac2 as a required component of cAMP/serotonin-dependent mood regulation and hippocampal neurogenesis.\",\n      \"method\": \"Epac2-knockout mouse behavioral tests (open field, fear conditioning), hippocampal cell proliferation assay, SSRI treatment\",\n      \"journal\": \"Translational psychiatry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic knockout with multiple behavioral phenotypes and neurogenesis readout, single lab\",\n      \"pmids\": [\"27598965\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Epac2 (Rap-GEF4) controls fusion pore expansion during insulin exocytosis by acutely recruiting two pore-restricting proteins, amisyn and dynamin-1, to the exocytosis site; cAMP elevation via GLP-1 receptor agonists or sulfonylureas restricts and slows fusion pore expansion and peptide release via this Epac2-dependent mechanism; this effect is absent in Epac2-/- (Rapgef4-/-) mice or upon Epac2 pharmacological inactivation.\",\n      \"method\": \"Total internal reflection fluorescence (TIRF) imaging of fusion pore dynamics, Epac2-/- (Rapgef4-/-) knockout mice, pharmacological Epac2 inactivation, Epac2 overexpression, amisyn/dynamin-1 recruitment imaging\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — genetic KO with pharmacological validation, live imaging of pore dynamics, identification of recruited effectors (amisyn, dynamin-1), multiple orthogonal approaches\",\n      \"pmids\": [\"31099751\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"RAPGEF4/EPAC2 is essential for exendin-4-induced autophagic flux in pancreatic beta-cells via a RAPGEF4/EPAC2→Ca2+→PPP3/calcineurin→TFEB axis; knockdown of RAPGEF4 prevents exendin-4-mediated cell survival and autophagic flux, while TFEB overexpression mimics the cytoprotective effect.\",\n      \"method\": \"siRNA knockdown of RAPGEF4 in INS-1E cells and human islets, chemical inhibitors, TFEB overexpression, db/db mouse in vivo treatment with exendin-4, lysosomal marker analysis\",\n      \"journal\": \"Autophagy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA knockdown and overexpression with defined autophagic and survival phenotypes, in vivo validation, single lab\",\n      \"pmids\": [\"34338148\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"EPAC2 overexpression in human microvascular endothelial cells suppresses Matrigel-driven tubulogenesis, inhibits cell migration, and changes cell morphology to a round shape; EPAC2 knockdown enhances tube formation, migration, and produces elongated cells with filopodia-like protrusions, identifying EPAC2 as a negative regulator of endothelial tube formation.\",\n      \"method\": \"RAPGEF4 overexpression and siRNA knockdown in HMVECs, Matrigel tube formation assay, migration assay, morphological imaging\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal gain- and loss-of-function with defined morphological and functional phenotypes, single lab\",\n      \"pmids\": [\"34593918\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"RAPGEF4 is required for proper electrophysiological maturation (resting membrane potential and inward sodium current) of neurons in the primate prefrontal cortex; CHD8 knockdown in human and macaque organotypic slices impairs neuronal maturation by downregulating RAPGEF4, and restoring RAPGEF4 expression rescues electrophysiological maturation in CHD8-deficient neurons.\",\n      \"method\": \"Patch-seq, single-nucleus multiomic analyses, shRNA knockdown of CHD8, RAPGEF4 restoration experiments in organotypic slices from macaque and human\",\n      \"journal\": \"Neuron\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — loss-of-function and rescue experiment in primate tissue with direct electrophysiological readout, multimodal analyses, two species validated\",\n      \"pmids\": [\"40398411\", \"37398253\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Hepatic EPAC2 (RAPGEF4) knockdown does not affect hepatic amino acid catabolism gene suppression, hyperaminoacidemia, or alpha-cell hyperplasia caused by glucagon receptor (GCGR) blockade, indicating EPAC2 (unlike PKA) is not required for the liver-alpha-cell loop; the GCGR→GNAS→PKA pathway (not EPAC2) mediates hepatic amino acid catabolism.\",\n      \"method\": \"siRNA/ASO-mediated knockdown of GCGR, GNAS, PKA, and EPAC2 in mouse liver; measurement of plasma amino acids, hepatic amino acid catabolism genes, and alpha-cell mass\",\n      \"journal\": \"Diabetes\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — negative result for EPAC2 established by direct knockdown in vivo with defined metabolic phenotype, single lab; negative finding reported explicitly\",\n      \"pmids\": [\"40095004\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"Rapgef4/Epac2 is upregulated in cortical excitatory and inhibitory neurons of Fmr1-knockout (fragile X syndrome model) mice; treatment with a specific EPAC2 antagonist restored cortical circuit function and ameliorated multiple behavioral phenotypes in Fmr1 KO mice, identifying EPAC2 as a potential therapeutic target for fragile X syndrome.\",\n      \"method\": \"Cell-type-specific translatomic sequencing (Patch-seq), EPAC2 antagonist treatment in Fmr1-KO mice, cortical circuit electrophysiology, behavioral assays\",\n      \"journal\": \"Neuron\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — translatomic identification plus pharmacological rescue with circuit and behavioral readouts, single lab\",\n      \"pmids\": [\"42155452\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"RAPGEF4 (Epac2/cAMP-GEFII) is a direct cAMP sensor and guanine nucleotide exchange factor for Rap1 that operates in a PKA-independent branch of cAMP signaling: upon cAMP binding—a conformational change structurally documented by crystallography—it forms a multiprotein complex with Rim2, Piccolo (Ca2+ sensor), SUR1, and L-type VDCC to integrate ATP, cAMP, and Ca2+ signals driving regulated exocytosis (most extensively characterized in pancreatic beta-cell insulin secretion); it also controls fusion pore expansion by recruiting amisyn and dynamin-1; in neurons it is activated by neuroligin, promotes Rap-dependent spine remodeling and synaptic depression, and is required for prefrontal cortex neuronal electrophysiological maturation; in cardiomyocytes it mediates GLP-1R-dependent ANP secretion; and in pancreatic beta-cells it drives GLP-1 agonist/sulfonylurea-stimulated secretion as well as GLP-1R agonist-induced autophagy via a Ca2+–calcineurin–TFEB axis.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"RAPGEF4 (Epac2/cAMP-GEFII) is a direct cAMP sensor and guanine nucleotide exchange factor for Rap1 that drives a PKA-independent branch of cAMP signaling controlling regulated exocytosis and cellular morphology [#0, #17]. In pancreatic beta-cells it nucleates a multiprotein exocytotic complex with Rim2, the Ca2+ sensor Piccolo, the KATP-channel subunit SUR1, and the L-type voltage-dependent Ca2+ channel (alpha1 1.2 subunit), integrating ATP, cAMP, and Ca2+ signals to potentiate incretin- and sulfonylurea-stimulated insulin secretion through a PKA-independent mechanism [#0, #1, #3, #6, #13]; cAMP binding inhibits its association with SUR1, regulating assembly of this complex [#4, #7]. Its membrane localization depends on the N-terminal cAMP-binding domain A, and SNAP-25 engagement couples it to the rapidly releasable granule pool [#10, #12], while at the fusion site it recruits amisyn and dynamin-1 to restrict and slow fusion pore expansion [#20]. In neurons, RAPGEF4 is activated by neuroligin and drives Rap-dependent dendritic spine shrinkage, AMPA receptor removal, and synaptic depression, with autism-associated missense mutations altering its GEF activity and spine morphology [#11]; it is also required for electrophysiological maturation of primate prefrontal cortical neurons downstream of CHD8 [#23]. Beyond these roles it mediates a GLP-1R\\u2192Epac2\\u2192atrial natriuretic peptide axis in cardiomyocytes [#14] and GLP-1R agonist-induced beta-cell autophagy via a Ca2+\\u2013calcineurin\\u2013TFEB pathway [#21]. RAPGEF4 acts as a negative regulator of endothelial migration and tubulogenesis [#9, #22].\",\n  \"teleology\": [\n    {\n      \"year\": 2000,\n      \"claim\": \"Established RAPGEF4 as a direct cAMP target that drives Ca2+-dependent exocytosis independently of PKA, defining a previously unrecognized branch of cAMP signaling.\",\n      \"evidence\": \"Co-IP/binding to Rim and Rim2 plus reconstituted exocytosis with PKA inhibitor controls\",\n      \"pmids\": [\"11056535\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct Rap1 GEF activity not yet linked to the exocytotic readout here\", \"Full effector complex not yet defined\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Showed the cAMP-GEFII\\u2013Rim2 pathway operates in native beta-cells in parallel with PKA to mediate incretin-potentiated insulin secretion, quantifying the relative contribution of each arm.\",\n      \"evidence\": \"Antisense knockdown in pancreatic islets with H-89 combinatorial pharmacology\",\n      \"pmids\": [\"11598134\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Antisense knockdown can have off-target effects\", \"Molecular link between Rim2 binding and secretion not resolved\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Demonstrated alternative promoter usage generates a liver-specific isoform lacking the first cAMP-binding and DEP domains yet retaining Rap1 GEF activity, separating catalytic activity from cAMP-sensing modules.\",\n      \"evidence\": \"cDNA cloning, expression mapping, and GEF activity assay\",\n      \"pmids\": [\"11707077\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological function of the liver isoform not established\", \"Regulation of the truncated isoform unclear\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Identified Piccolo as the Ca2+-sensing component of the cAMP-GEFII\\u00b7Rim2 complex, explaining how Ca2+ dependence is conferred on cAMP-induced exocytosis.\",\n      \"evidence\": \"Co-IP, Ca2+-dependent dimerization assays, antisense knockdown with secretion readout\",\n      \"pmids\": [\"12401793\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry of the complex not defined\", \"Direct demonstration of Ca2+ sensing in vivo limited\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Resolved the full beta-cell signaling complex (cAMP-GEFII, Rim2, Piccolo, SUR1, L-type VDCC) and the SUR1\\u2013NBF1 interaction, showing how ATP, cAMP, and Ca2+ signals are physically integrated at the exocytotic site.\",\n      \"evidence\": \"Co-IP, immunolocalization, SUR1-knockout electrophysiology, dominant-negative Rim2\",\n      \"pmids\": [\"12601083\", \"14660679\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Spatial organization of the complex at single-granule resolution unresolved\", \"Mechanism of cAMP-dependent Cl- influx incompletely defined\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Demonstrated cAMP regulates the assembly state of the KATP/cAMP-GEFII/Piccolo/VDCC complex, providing a switch mechanism whereby cAMP binding releases RAPGEF4 from SUR1.\",\n      \"evidence\": \"Co-IP and pull-down with 8-bromo-cAMP and ATP perturbations\",\n      \"pmids\": [\"15561922\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Biochemical assays only; in-cell dynamics of assembly not shown\", \"Single lab\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Linked RAPGEF4 to GLP-1-stimulated ryanodine receptor Ca2+ release and mitochondrial ATP synthesis, broadening its role beyond direct exocytic machinery to intracellular Ca2+ mobilization.\",\n      \"evidence\": \"Dominant-negative mutant and pharmacological inhibitors with mitochondrial ATP/Ca2+ imaging in MIN6 cells\",\n      \"pmids\": [\"12410638\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Dominant-negative specificity not orthogonally confirmed\", \"Single cell line and lab\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Generalized the PKA-independent Epac2 exocytic arm to neuroendocrine melanotrophs and assigned it to a distinct kinetic component of secretion.\",\n      \"evidence\": \"Patch-clamp capacitance in pituitary slices with Epac- and PKA-selective agonists\",\n      \"pmids\": [\"15994184\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular effectors in melanotrophs not identified\", \"Single lab\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Mapped RAPGEF4 membrane targeting to cAMP-binding domain A and showed this localization is required for secretory function, explaining isoform-specific activity.\",\n      \"evidence\": \"Domain deletion/splice variant analysis, membrane-targeting rescue, secretion assays, KO mice\",\n      \"pmids\": [\"19170062\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Membrane lipid/protein anchor for domain A not identified\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Connected RAPGEF4 to the SNARE machinery via SNAP-25, defining its requirement for cAMP potentiation of the immediately releasable granule pool.\",\n      \"evidence\": \"Protein-binding assays plus capacitance measurements with truncated SNAP-25/BoNT/A in INS-1 cells\",\n      \"pmids\": [\"19509185\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct vs Rim2-bridged SNAP-25 binding not resolved\", \"Single lab\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Defined a neuronal role: neuroligin-activated RAPGEF4 drives Rap-dependent spine shrinkage and synaptic depression, with autism mutations perturbing its GEF activity and synaptic output.\",\n      \"evidence\": \"Activation/inhibition in cortical neurons, spine imaging, electrophysiology, neuroligin Co-IP, mutant GEF assays\",\n      \"pmids\": [\"19734897\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Rap effectors mediating spine remodeling not fully mapped\", \"In vivo behavioral consequence of mutants not tested here\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Established that sulfonylureas (except gliclazide) act partly through Epac2/Rap1, defining RAPGEF4 as a pharmacological target of these drugs.\",\n      \"evidence\": \"Pharmacological comparison of sulfonylureas with Epac2/Rap1 activation assays\",\n      \"pmids\": [\"22118705\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Review-level synthesis; direct binding mode of each drug to Epac2 not detailed\", \"Single group\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Extended RAPGEF4 to cardiac physiology, defining a GLP-1R\\u2192Epac2\\u2192ANP axis that lowers blood pressure.\",\n      \"evidence\": \"Membrane translocation imaging and multiple knockout mouse lines with ANP and vasorelaxation readouts\",\n      \"pmids\": [\"23542788\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Rap effector coupling to ANP granule release in cardiomyocytes not detailed\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Demonstrated a developmental/endocytic role for Rapgef4 downstream of Gnas/cAMP in renal proximal tubule growth and transport.\",\n      \"evidence\": \"Morpholino knockdown in Xenopus and agonist treatment with albumin uptake assays in human tubular cells\",\n      \"pmids\": [\"23352791\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Downstream Rap effectors in tubular cells unidentified\", \"Morpholino off-target effects\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Identified an EPAC2\\u2192CALR\\u2192LIF/PTGS2 axis in endometrial gland epithelium, expanding RAPGEF4 to reproductive tissue gene regulation.\",\n      \"evidence\": \"siRNA knockdown of EPAC2 and CALR with selective cAMP analogs and senescence assays\",\n      \"pmids\": [\"25378661\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism linking EPAC2 to CALR expression unknown\", \"Single lab\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Provided structural basis for cAMP-induced activation, showing dynamic conformational changes accompany cAMP sensing and Rap GEF activity.\",\n      \"evidence\": \"Crystallographic analysis (review synthesizing prior structures)\",\n      \"pmids\": [\"26390815\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Structures of full effector complex not resolved\", \"Review format\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Showed adenylyl-cyclase isoform selectivity (AC6 not AC7) routes PACAP-driven cAMP to Epac2/p38 signaling, illustrating compartmentalized cAMP signaling through RAPGEF4.\",\n      \"evidence\": \"shRNA knockdown of AC6/AC7 with phospho-p38 readout and cholesterol depletion in PC12 cells\",\n      \"pmids\": [\"25769305\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct Epac2-p38 coupling mechanism not defined\", \"Single lab\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Implicated RAPGEF4 in mood regulation and hippocampal neurogenesis via knockout behavioral phenotypes rescuable by SSRI.\",\n      \"evidence\": \"Epac2-knockout mouse behavioral tests, neurogenesis assay, fluoxetine treatment\",\n      \"pmids\": [\"27598965\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular pathway linking Epac2 to neurogenesis unresolved\", \"Single lab\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Defined a fusion-pore-restricting function: RAPGEF4 acutely recruits amisyn and dynamin-1 to slow pore expansion, revealing control of the kinetics of granule cargo release.\",\n      \"evidence\": \"TIRF imaging of fusion pore dynamics in Rapgef4-/- mice with effector recruitment imaging and pharmacology\",\n      \"pmids\": [\"31099751\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether Rap1 GEF activity is required for recruitment not resolved\", \"Direct binding of Epac2 to amisyn/dynamin-1 not biochemically mapped\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Established a RAPGEF4\\u2192Ca2+\\u2192calcineurin\\u2192TFEB axis driving exendin-4-induced autophagy and beta-cell survival, linking RAPGEF4 to cytoprotective transcriptional programs.\",\n      \"evidence\": \"siRNA knockdown in INS-1E cells and human islets, TFEB overexpression, db/db mouse exendin-4 treatment\",\n      \"pmids\": [\"34338148\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Step linking Rap1 activation to calcineurin not defined\", \"Single lab\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Identified EPAC2 as a negative regulator of endothelial tube formation and migration, consistent with its earlier anti-chemotactic role.\",\n      \"evidence\": \"Reciprocal overexpression and siRNA in HMVECs with Matrigel and migration assays\",\n      \"pmids\": [\"34593918\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Cytoskeletal effector pathway not fully mapped\", \"Single lab\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Placed RAPGEF4 downstream of CHD8 as required for primate prefrontal cortical neuron electrophysiological maturation, demonstrated by knockdown and rescue.\",\n      \"evidence\": \"Patch-seq, single-nucleus multiomics, CHD8 knockdown and RAPGEF4 restoration in macaque and human organotypic slices\",\n      \"pmids\": [\"40398411\", \"37398253\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular targets driving membrane potential/Na+ current changes not identified\", \"Whether GEF activity mediates maturation untested\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Showed hepatic EPAC2 is dispensable for the GCGR\\u2192GNAS\\u2192PKA liver-alpha-cell loop, sharpening the boundary between PKA-dependent and Epac2-dependent cAMP responses.\",\n      \"evidence\": \"siRNA/ASO knockdown of GCGR/GNAS/PKA/EPAC2 in mouse liver with metabolic readouts (negative result for EPAC2)\",\n      \"pmids\": [\"40095004\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Negative result; possible compensation or incomplete knockdown not excluded\", \"Single lab\"]\n    },\n    {\n      \"year\": 2026,\n      \"claim\": \"Identified EPAC2 upregulation in fragile X model cortex and showed pharmacological antagonism rescues circuit and behavioral phenotypes, nominating it as a therapeutic target.\",\n      \"evidence\": \"Cell-type-specific translatomics, EPAC2 antagonist treatment in Fmr1-KO mice, circuit electrophysiology and behavior\",\n      \"pmids\": [\"42155452\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism linking EPAC2 upregulation to circuit dysfunction not defined\", \"Single lab\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How RAPGEF4 GEF/Rap1 activity is mechanistically partitioned among its many tissue-specific outputs (exocytosis, fusion-pore control, spine remodeling, autophagy, neuronal maturation) remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified model linking Rap1 effector choice to distinct cellular outputs\", \"Structures of full physiological effector complexes not solved\", \"Whether catalytic GEF activity is required for all phenotypes not systematically tested\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140299\", \"supporting_discovery_ids\": [0, 17]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [2, 11, 9]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [0, 17]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [6, 10, 14]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [10]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 17]},\n      {\"term_id\": \"R-HSA-5653656\", \"supporting_discovery_ids\": [0, 6, 20]},\n      {\"term_id\": \"R-HSA-9612973\", \"supporting_discovery_ids\": [21]}\n    ],\n    \"complexes\": [\n      \"cAMP-GEFII\\u00b7Rim2\\u00b7Piccolo\\u00b7SUR1\\u00b7L-type VDCC exocytotic complex\"\n    ],\n    \"partners\": [\n      \"RIMS2\",\n      \"PCLO\",\n      \"ABCC8\",\n      \"CACNA1C\",\n      \"SNAP25\",\n      \"NLGN1\",\n      \"DNM1\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":6,"faith_pct":100.0}}